Dasatinib

Form: Tablet

Strength: 20 mg, 50 mg, 70 mg, 100 mg, 140 mg

Reference Brands: Sprycel® (EU & US)

Category: Oncology Cancer Care

Dasatinib is an oral tyrosine kinase inhibitor (TKI) used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). By targeting the BCR-ABL fusion protein, Dasatinib effectively blocks the signals that drive the growth of cancer cells. Available in tablet forms of 20 mg, 50 mg, 70 mg, 100 mg, and 140 mg, it offers a flexible dosing regimen for oncologists. Sprycel® (Dasatinib) is widely available in both the US and EU, providing essential treatment options for leukemia patients. This presents significant B2B opportunities for pharmaceutical manufacturers in these markets.